Variations in NAG‑1 expression of human gastric carcinoma and normal gastric tissues

Yang,Gongli; Tan,Qinhua; Xie,Yongmei; Wei,Bin; Chen,Zhixin; Tang,Chengwei; Li,Shengbao; Wang,Chunhui

doi:10.3892/etm.2013.1361

Variations in NAG‑1 expression of human gastric carcinoma and normal gastric tissues

Authors:
- Gongli Yang
- Qinhua Tan
- Yongmei Xie
- Bin Wei
- Zhixin Chen
- Chengwei Tang
- Shengbao Li
- Chunhui Wang
View Affiliations

Affiliations: Department of Gastroenterology, Nanfang Hospital, Southern Medical University, Guangzhou, Guangdong 510515, P.R. China, Department of Gastroenterology, West China Hospital, Sichuan University, Chengdu, Sichuan 610041, P.R. China, Department of Gastroenterology, Taihe Hospital, Hubei Medical University, Shiyan, Hubei 442000, P.R. China
Published online on: October 24, 2013 https://doi.org/10.3892/etm.2013.1361
Pages: 241-245

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

Nonsteroidal anti‑inflammatory drug‑activated gene‑1 (NAG‑1), a member of the transforming growth factor β (TGF‑β) superfamily, has been demonstrated to possess antitumorigenic and proapoptotic activities in gastric cancer cells. In the present study, the expression of NAG‑1 was assessed in human gastric carcinoma, tumor‑adjacent normal tissues and normal gastric mucosa, with the aim to investigate the role of NAG‑1 in the carcinogenesis and development of gastric carcinoma. NAG‑1 protein expression was evaluated using immunohistochemical staining, while the expression of NAG‑1 mRNA was evaluated using reverse transcription‑polymerase chain reaction. It was observed that adenocarcinoma tissues had a lower expression of NAG‑1 than normal gastric tissues. Furthermore, moderately and well‑differentiated adenocarcinoma tissues expressed more NAG‑1 protein than the poorly differentiated adenocarcinoma tissues. The expression of NAG‑1 protein in adenocarcinoma tissues did not correlate with tumor‑node‑metastasis staging, infiltration degree or tumor size. The NAG‑1 mRNA expression in adenocarcinoma tissues was also lower than that in normal gastric tissues. In conclusion, NAG‑1 was poorly expressed in adenocarcinoma tissues and inversely correlated with the degree of tumor differentiation. These results indicate that NAG‑1 may have an anti‑oncogenic function in the carcinogenesis and development of gastric carcinoma, and that its attenuated or absent expression may lead to gastric carcinogenesis.

View Figures

View References

1	Wang R, Guo L, Wang P, et al: Chemoprevention of cancers in gastrointestinal tract with cyclooxygenase 2 inhibitors. Curr Pharm Des. 19:115–125. 2012.PubMed/NCBI
2	Wang C, Wang J and Bai P: Troglitazone induces apoptosis in gastric cancer cells through the NAG-1 pathway. Mol Med Rep. 4:93–97. 2011.PubMed/NCBI
3	Lee DH, Yang Y, Lee SJ, et al: Macrophage inhibitory cytokine-1 induces the invasiveness of gastric cancer cells by up-regulating the urokinase-type plasminogen activator system. Cancer Res. 63:4648–4655. 2003.PubMed/NCBI
4	Park JY, Park KH, Bang S, Kim MH, Koh SS and Song SY: Expression of nonsteroidal anti-inflammatory drug-activated gene-1 (NAG-1) inversely correlates with tumor progression in gastric adenomas and carcinomas. J Cancer Res Clin Oncol. 134:1029–1035. 2008. View Article : Google Scholar : PubMed/NCBI
5	Baek SJ, Kim KS, Nixon JB, Wilson LC and Eling TE: Cyclooxygenase inhibitors regulate the expression of a TGF-beta superfamily member that has proapoptotic and antitumorigenic activities. Mol Pharmacol. 59:901–908. 2001.PubMed/NCBI
6	Baek SJ, Wilson LC and Eling TE: Resveratrol enhances the expression of non-steroidal anti-inflammatory drug-activated gene (NAG-1) by increasing the expression of p53. Carcinogenesis. 23:425–434. 2002. View Article : Google Scholar : PubMed/NCBI
7	Wilson LC, Baek SJ, Call A and Eling TE: Nonsteroidal anti-inflammatory drug-activated gene (NAG-1) is induced by genistein through the expression of p53 in colorectal cancer cells. Int J Cancer. 105:747–753. 2003. View Article : Google Scholar : PubMed/NCBI
8	Bottone FG Jr, Baek SJ, Nixon JB and Eling TE: Diallyl disulfide (DADS) induces the antitumorigenic NSAID-activated gene (NAG-1) by a p53-dependent mechanism in human colorectal HCT 116 cells. J Nutr. 132:773–778. 2002.PubMed/NCBI
9	Lee SH, Kim JS, Yamaguchi K, Eling TE and Baek SJ: Indole-3-carbinol and 3,3′-diindolylmethane induce expression of NAG-1 in a p53-independent manner. Biochem Biophys Res Commun. 328:63–69. 2005.
10	Newman D, Sakaue M, Koo JS, et al: Differential regulation of nonsteroidal anti-inflammatory drug-activated gene in normal human tracheobronchial epithelial and lung carcinoma cells by retinoids. Mol Pharmacol. 63:557–564. 2003. View Article : Google Scholar : PubMed/NCBI
11	Baek SJ, Kim JS, Nixon JB, DiAugustine RP and Eling TE: Expression of NAG-1, a transforming growth factor-beta superfamily member, by troglitazone requires the early growth response gene EGR-1. J Biol Chem. 279:6883–6892. 2004. View Article : Google Scholar : PubMed/NCBI
12	Li PX, Wong J, Ayed A, et al: Placental transforming growth factor-beta is a downstream mediator of the growth arrest and apoptotic response of tumor cells to DNA damage and p53 overexpression. J Biol Chem. 275:20127–20135. 2000. View Article : Google Scholar : PubMed/NCBI
13	Bootcov MR, Bauskin AR, Valenzuela SM, et al: MIC-1, a novel macrophage inhibitory cytokine, is a divergent member of the TGF-beta superfamily. Proc Natl Acad Sci USA. 94:11514–11519. 1997. View Article : Google Scholar : PubMed/NCBI
14	Hromas R, Hufford M, Sutton J, Xu D, Li Y and Lu L: PLAB, a novel placental bone morphogenetic protein. Biochim Biophys Acta. 1354:40–44. 1997. View Article : Google Scholar : PubMed/NCBI
15	Paralkar VM, Vail AL, Grasser WA, et al: Cloning and characterization of a novel member of the transforming growth factor-beta/bone morphogenetic protein family. J Biol Chem. 273:13760–13767. 1998. View Article : Google Scholar : PubMed/NCBI
16	Böttner M, Laaff M, Schechinger B, Rappold G, Unsicker K and Suter-Crazzolara C: Characterization of the rat, mouse, and human genes of growth/differentiation factor-15/macrophage inhibiting cytokine-1 (GDF-15/MIC-1). Gene. 237:105–111. 1999.PubMed/NCBI
17	Bauskin AR, Zhang HP, Fairlie WD, et al: The propeptide of macrophage inhibitory cytokine (MIC-1), a TGF-beta superfamily member, acts as a quality control determinant for correctly folded MIC-1. EMBO J. 19:2212–2220. 2000. View Article : Google Scholar : PubMed/NCBI
18	Tan M, Wang Y, Guan K and Sun Y: PTGF-beta, a type beta transforming growth factor (TGF-beta) superfamily member, is a p53 target gene that inhibits tumor cell growth via TGF-beta signaling pathway. Proc Natl Acad Sci USA. 97:109–114. 2000. View Article : Google Scholar : PubMed/NCBI
19	Liu T, Bauskin AR, Zaunders J, et al: Macrophage inhibitory cytokine 1 reduces cell adhesion and induces apoptosis in prostate cancer cells. Cancer Res. 63:5034–5040. 2003.PubMed/NCBI
20	Lambert JR, Kelly JA, Shim M, et al: Prostate derived factor in human prostate cancer cells: gene induction by vitamin D via a p53-dependent mechanism and inhibition of prostate cancer cell growth. J Cell Physiol. 208:566–574. 2006. View Article : Google Scholar : PubMed/NCBI
21	Baek SJ, Okazaki R, Lee SH, et al: Nonsteroidal anti-inflammatory drug-activated gene-1 over expression in transgenic mice suppresses intestinal neoplasia. Gastroenterology. 131:1553–1560. 2006. View Article : Google Scholar : PubMed/NCBI
22	Brown DA, Ward RL, Buckhaults P, et al: MIC-1 serum level and genotype: associations with progress and prognosis of colorectal carcinoma. Clin Cancer Res. 9:2642–2650. 2003.PubMed/NCBI
23	Senapati S, Rachagani S, Chaudhary K, Johansson SL, Singh RK and Batra SK: Overexpression of macrophage inhibitory cytokine-1 induces metastasis of human prostate cancer cells through the FAK-RhoA signaling pathway. Oncogene. 29:1293–1302. 2010. View Article : Google Scholar : PubMed/NCBI
24	Kim KK, Lee JJ, Yang Y, You KH and Lee JH: Macrophage inhibitory cytokine-1 activates AKT and ERK-1/2 via the transactivation of ErbB2 in human breast and gastric cancer cells. Carcinogenesis. 29:704–712. 2008. View Article : Google Scholar : PubMed/NCBI
25	Baek KE, Yoon SR, Kim JT, et al: Upregulation and secretion of macrophage inhibitory cytokine-1 (MIC-1) in gastric cancers. Clin Chim Acta. 401:128–133. 2009. View Article : Google Scholar : PubMed/NCBI
26	Pang RP, Zhou JG, Zeng ZR, et al: Celecoxib induces apoptosis in COX-2 deficient human gastric cancer cells through Akt/GSK3beta/NAG-1 pathway. Cancer Lett. 251:268–277. 2007. View Article : Google Scholar
27	Jang TJ, Kang HJ, Kim JR and Yang CH: Non-steroidal anti-inflammatory drug activated gene (NAG-1) expression is closely related to death receptor-4 and -5 induction, which may explain sulindac sulfide induced gastric cancer cell apoptosis. Carcinogenesis. 25:1853–1858. 2004. View Article : Google Scholar
28	Mimeault M and Batra SK: Divergent molecular mechanisms underlying the pleiotropic functions of macrophage inhibitory cytokine-1 in cancer. J Cell Physiol. 224:626–635. 2010. View Article : Google Scholar : PubMed/NCBI
29	Wang X, Baek SJ and Eling TE: The diverse roles of nonsteroidal anti-inflammatory drug activated gene (NAG-1/GDF15) in cancer. Biochem Pharmacol. 85:597–606. 2013. View Article : Google Scholar : PubMed/NCBI
30	Kim KS, Baek SJ, Flake GP, Loftin CD, Calvo BF and Eling TE: Expression and regulation of nonsteroidal anti-inflammatory drug-activated gene (NAG-1) in human and mouse tissue. Gastroenterology. 122:1388–1398. 2002. View Article : Google Scholar : PubMed/NCBI
31	Kadowaki M, Yoshioka H, Kamitani H, Watanabe T, Wade PA and Eling TE: DNA methylation-mediated silencing of nonsteroidal anti-inflammatory drug-activated gene (NAG-1/GDF15) in glioma cell lines. Int J Cancer. 130:267–277. 2012. View Article : Google Scholar : PubMed/NCBI